LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
12 avr. 2022 13h53 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...